Abbvie Biotech Ventures

Investor type

CVC

Founded

2013

AUM

-

Location

United States

Investment Ticket

$0-1 m

Investment Stage

Seed Series A

Region of investment

North America Europe
Investor profile last updated: 07 January, 2022

Profile

As tomorrow’s innovations are developed by today’s entrepreneurs, we invest in transformational scientific opportunities aligned with our core R&D interests to gain access to next-generation science and build relationships with proven and emerging scientific leaders.

We’re AbbVie’s corporate strategic venture capital arm
Investing since 2009, we focus exclusively on novel, transformational therapeutics at discovery and pre-clinical stages. Aligning with AbbVie’s strategic focus, our investments address critical needs in oncology, immunology, and neuroscience. We offer our partners access to AbbVie’s vast internal network of experts in all phases of drug development, from drug discovery through successful commercialization.


Our current portfolio is comprised of over 20 companies based in the US and Europe. Targeting six to eight new investments annually, predominantly at the Seed or Series A stage, we have the capability and flexibility to lead or co-lead a syndicate. Our team of seven investing professionals is based in three locations: Boston, San Francisco and Chicago areas.

Industry

Fashion/Beauty Healthcare Services HealthTech Biotechnology Pharmaceuticals Technology Life Sciences

Contacts

Name
Title
Email
avatar
Peter Zuccolotto PhD RAC Regulatory Affairs Manager ANZ
Regulatory Affairs Manager ANZ
-
avatar
Robert A. Michael Vice Chairman, Finance and Commercial Operations and Chief Financial Officer
Vice Chairman, Finance and Commercial Operations and Chief Financial Officer
-
Upgrade to see contacts
avatar
HlDpr4uPAQYxK7iF HlDpr4uPAQYxK7iF
HlDpr4uPAQYxK7iF
avatar
HlDpr4uPAQYxK7iF HlDpr4uPAQYxK7iF
HlDpr4uPAQYxK7iF
avatar
HlDpr4uPAQYxK7iF HlDpr4uPAQYxK7iF
HlDpr4uPAQYxK7iF
Investment-team contacts for Abbvie Biotech Ventures — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Abbvie Biotech Ventures

Abbvie Biotech Ventures operates as a corporate VC (CVC). It backs companies at Seed and Series A, writing tickets of $0-1 m.
Abbvie Biotech Ventures is located in United States.
Abbvie Biotech Ventures was founded in 2013.
Abbvie Biotech Ventures invests in companies and startups in Fashion/Beauty, Healthcare Services, HealthTech, Biotechnology, Pharmaceuticals, Technology, Life Sciences.
Abbvie Biotech Ventures invests in companies and startups in North America, Europe.
Abbvie Biotech Ventures invests in companies and startups at Seed, Series A.
Abbvie Biotech Ventures usually invests $0-1 m on average.
Abbvie Biotech Ventures can be reached through its website abbviebiotechventures.com, its LinkedIn page and its X account. Its general enquiries address is -. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Abbvie Biotech Ventures — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Abbvie Biotech Ventures directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 07 January, 2022. Something out of date here? Report it — we re-run that firm within 48h and get back to you.